Estrogenicity of novel phase I and phase II metabolites of zearalenone and cis-zearalenone

被引：50
|
作者：
Drzymala, Sarah S. [1 ]
Binder, Jennifer [2 ]
Brodehl, Antje [1 ]
Penkert, Martin [3 ]
Rosowski, Mark [2 ]
Garbe, Leif-Alexander [4 ]
Koch, Matthias [1 ]
机构：
[1] BAM Fed Inst Mat Res & Testing, Dept Analyt Chem, Reference Mat, D-12489 Berlin, Germany
[2] Tech Univ Berlin, Dept Biotechnol, Inst Med Biotechnol, D-13355 Berlin, Germany
[3] Humboldt Univ, Dept Chem, D-12489 Berlin, Germany
[4] Tech Univ Berlin, Dept Biotechnol, Inst Bioanalyt, D-13355 Berlin, Germany
来源：
TOXICON | 2015年 / 105卷
关键词：
Zearalenone; Mycotoxin; MCF-7; E-screen assay; Estrogenicity; Isomerization; ENDOCRINE-DISRUPTING CHEMICALS; DERIVATIVES;
D O I：
10.1016/j.toxicon.2015.08.027
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Zearalenone and its cis-isomer, cis-zearalenone, are nonsteroidal mycotoxins that elicit an estrogenic response upon binding to the estrogen receptor. This study compares the estrogenicity of eleven congeners including novel metabolites as 15-OH-zearalenone, zearalenone-14-sulfate, alpha-cis-zearalenol and beta-cis-zearalenol using the E-Screen assay. Overall, a change in the configuration from trans to cis retains significant estrogenic activity. In contrast, alterations of the aromatic moiety including hydroxylation and sulfation showed a markedly decreased estrogenicity when compared to zearalenone. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码：10 / 12
页数：3
相关论文
共 50 条
  • [41] In vitro profiling of phase I and II metabolites of butoconazole from multiple species
    Haspel, Howard C.
    Liu, Sheng
    Mitchell, Sarah
    Zhang, Xin
    Sheldon, Adrian
    Liu, Hongjun
    Yang, Ju
    DRUG METABOLISM REVIEWS, 2006, 38 : 165 - 165
  • [42] Identification of phase-I and phase-II metabolites and the metabolic pathway of the novel synthetic cannabinoid 5F-EDMB-PICA in vitro
    Gao, Yujie
    Shi, Kaiting
    Wang, Peipei
    Liu, Xinyu
    Liu, Chenxi
    Luo, Liya
    Lin, Yanchen
    Yang, Lin
    Yang, Rongji
    Liao, Linchuan
    ARCHIVES OF TOXICOLOGY, 2024, 98 (09) : 2879 - 2888
  • [43] LC-ESI-MS/MS identification and characterization of ponatinib in vivo phase I and phase II metabolites
    Attwa, Mohamed W.
    Kadi, Adnan A.
    Darwish, Hany W.
    Amer, Sawsan M.
    AlRabiah, Haitham
    CLINICA CHIMICA ACTA, 2018, 485 : 144 - 151
  • [44] Phase I and phase II Study Groups
    不详
    ONKOLOGIE, 1998, 21 : 1 - 70
  • [45] Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives
    Sverdlov, Oleksandr
    Wong, Weng Kee
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2014, 48 (05) : 601 - 612
  • [46] Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives
    Oleksandr Sverdlov
    Weng Kee Wong
    Therapeutic Innovation & Regulatory Science, 2014, 48 : 601 - 612
  • [47] Novel Methodologic Approaches to Phase I, II, and III Trials
    Yeatts, Sharon D.
    STROKE, 2013, 44 (06) : S116 - S118
  • [48] A phase I/II study of DHP107, a novel oral paclitaxel formulation, in patients with advanced solid tumors (phase I) and gastric cancer (phase II).
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Kim, Tae Won
    Kim, Sung-Bae
    Lim, Hyeong-Seok
    Bae, Kyun-Seop
    Park, Sook Ryun
    Jo, Yeong-Woo
    Cho, Hyun Ju
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [49] IDENTIFICATION OF PHASE-I AND PHASE-II METABOLITES OF FLUPHENAZINE IN RAT BILE - INTACT GLUCURONIDE AND SULFATE CONJUGATES
    JACKSON, CJC
    HUBBARD, JW
    MCKAY, G
    COOPER, JK
    HAWES, EM
    MIDHA, KK
    DRUG METABOLISM AND DISPOSITION, 1991, 19 (01) : 188 - 193
  • [50] Determination of buprenorphine, naloxone and phase I and phase II metabolites in rat whole blood by LC-MS/MS
    Cohier, Camille
    Salle, Sophie
    Fontova, Anne
    Megarbane, Bruno
    Roussel, Olivier
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2020, 180
12345